H35.3111

🧬 ICD-10-CM H35.3111 — Nonexudative AMD, Right Eye, Early Dry Stage

Billable Code Confirmed

H35.3111 is a valid, billable 7-character ICD-10-CM code for FY2025. All seven characters are present: H35 (category) + .3 (degeneration of macula) + 1 (nonexudative) + 1 (right eye) + 1 (early dry stage). No additional characters required — this code is complete and will process on a claim.

Non-Billable Parent Codes — Do Not Submit These

The following codes in the H35.3111 family tree are non-billable headers and will reject on a claim:

• ❌ H35.311 — 6-character — missing staging character
• ❌ H35.31 — 5-character — missing laterality AND staging
• ❌ H35.3 — 4-character — subcategory only Always submit H35.3111 (all 7 characters) for early dry AMD, right eye.

---

🔍 Code Description

H35.3111 classifies nonexudative (dry) age-related macular degeneration of the right eye at the early dry stage — the earliest clinically recognized phase of AMD characterized by the presence of medium-sized drusen (≥63μm to <125μm) without associated pigmentary abnormalities at the macula, in the right eye.^1,2

At this stage, patients are typically asymptomatic or report only subtle changes — slight difficulty adapting to low-light environments, mildly reduced contrast sensitivity, or no symptoms at all. Central visual acuity is generally preserved (20/20 to 20/40). The diagnosis is almost always made incidentally during a dilated fundus examination, underscoring the importance of routine ophthalmologic screening in patients over age 65. The primary management goal at this stage is monitoring for progression — to intermediate stage (H35.3112), advanced geographic atrophy (H35.3113-H35.3114), or conversion to wet AMD (H35.3211).²

---

🌳 Code Tree / Hierarchy

H35.3 Degeneration of Macula and Posterior Pole  
│  
├── H35.31 Nonexudative AMD ❌ Non-billable header  
│ │  
│ └── H35.311 Right Eye ❌ Non-billable header  
│ │  
│ ├── H35.3110 Right eye, stage unspecified ⚠️ last resort  
│ ├── H35.3111 Right eye, EARLY DRY stage ◀ THIS CODE ✅  
│ ├── H35.3112 Right eye, intermediate dry stage  
│ ├── H35.3113 Right eye, advanced atrophic, w/o subfoveal  
│ └── H35.3114 Right eye, advanced atrophic, w/ subfoveal

The 7th Character Is the Stage — Remember It Like This

Think of the 7th character as a severity dial for nonexudative AMD:

• 0 = Unknown (don’t use if avoidable)
• 1 = Early — medium drusen, no pigment changes
• 2 = Intermediate — large drusen or pigment changes
• 3 = Advanced, not at center — geographic atrophy, fovea spared
• 4 = Advanced, at center — geographic atrophy at fovea, severe vision loss

The 7th character is the same across all laterality variants — right (H35.311x), left (H35.312x), bilateral (H35.313x), and unspecified (H35.319x). Memorize the digit-to-stage mapping once and it applies everywhere in the nonexudative AMD family.

---

📊 Early Dry AMD — Clinical Staging Criteria

Beckman Clinical Classification (ICD-10-CM Aligned)^2,3

Stage	ICD-10-CM Code (Right Eye)	Drusen Criteria	Pigmentary Changes	Typical VA
Normal aging changes	Not AMD — no code	Small drusen only (<63μm / drupelets)	None	20/20
Early AMD ← This code	H35.3111	Medium drusen ≥63μm to <125μm	None	20/20-20/40
Intermediate AMD	H35.3112	Large drusen ≥125μm and/or pigmentary abnormalities	May be present	20/25-20/80
Advanced AMD (GA, no subfoveal)	H35.3113	Geographic atrophy of RPE, not involving fovea	Significant	Variable — fovea spared
Advanced AMD (GA, subfoveal)	H35.3114	Geographic atrophy involving foveal center	Significant	20/200+ — legal blindness
Late AMD (wet/neovascular)	H35.3211	CNV present — active	Significant	Rapid acute drop

Drusen Size Is the Defining Criterion for H35.3111

The critical boundary for early AMD coding is medium-sized drusen (≥63μm to <125μm) WITHOUT pigmentary abnormalities. [web:86] Key clinical distinctions:

• Small drusen (<63μm) = normal aging (“drupelets”) — do NOT code as AMD; they carry no clinically significant progression risk
• Medium drusen (≥63-<125μm), NO pigment changes → H35.3111 Early dry stage
• Large drusen (≥125μm) OR any pigment changes → H35.3112 Intermediate — not early

If the ophthalmologist documents “medium drusen with focal RPE pigmentary changes” — this is H35.3112 (intermediate), not H35.3111. The presence of ANY AMD-associated pigmentary abnormality upgrades the stage regardless of drusen size. Query when documentation is ambiguous.

AREDS Simplified Severity Scale — Risk Scoring³

The AREDS Simplified Severity Scale quantifies 5-year risk of progression to advanced AMD in at least one eye using a point system. Each eye contributes up to 2 points (1 for large drusen ≥125μm, 1 for AMD-associated pigmentary abnormality).

AREDS Score	5-Year Risk of Advanced AMD	H35.31x Stage Correlation
0 points	~0.5%	Normal aging / very early AMD
1 point	~3%	Transitional early/intermediate
2 points	~12%	Intermediate AMD — H35.3112
3 points	~25%	Intermediate to early advanced
4 points	~50%	Advanced AMD — H35.3113/H35.3114

Early Dry AMD (H35.3111) Typically = AREDS Score 0-1

A patient with bilateral medium drusen without pigment changes scores 0 points per eye under the AREDS system (0 points — no large drusen, no pigment changes). This maps cleanly to early AMD and supports the H35.3111 / H35.3121 bilateral assignment. An AREDS score of 1 in the right eye (e.g., a single large drusen identified) would push toward H35.3112 — re-examine the documentation carefully before confirming H35.3111.

---

✅ Includes

The following clinical terms map to H35.3111 — right eye, early dry stage:¹

• Nonexudative AMD, right eye, early dry stage
• Dry AMD, right eye, early stage (Beckman classification)
• Medium drusen (≥63μm to <125μm), right eye, without pigmentary abnormalities, age-related
• Early age-related maculopathy (ARM), right eye, nonexudative
• AMD, early, right eye — no CNV, no geographic atrophy, no pigment changes

Do NOT Include These — They Map to More Specific Codes

• “Medium drusen WITH pigmentary changes, right eye” → H35.3112 (intermediate)
• “Large drusen, right eye” → H35.3112 (intermediate)
• “Geographic atrophy, right eye” → H35.3113 or H35.3114 (advanced)
• “Choroidal neovascularization, right eye” → H35.3211 (wet AMD)
• “Small drusen only (drupelets)” → NOT AMD — no code; normal aging

---

❌ Excludes

Excludes 2 — Assign Diabetic Code Instead When DM Is the Etiology¹

Code Range	Description	Action
E08.311-E08.359	Drug/chemical-induced DM with diabetic retinopathy	Use diabetic retinopathy code — NOT H35.3111
E10.311-E10.359	Type 1 DM with diabetic retinopathy	Use diabetic retinopathy code — NOT H35.3111
E11.311-E11.359	Type 2 DM with diabetic retinopathy	Use diabetic retinopathy code — NOT H35.3111
E13.311-E13.359	Other specified DM with diabetic retinopathy	Use diabetic retinopathy code — NOT H35.3111

Diabetic Patients Can Have Both — With Explicit Documentation

A diabetic patient can have concurrent early dry AMD and diabetic retinopathy as separately documented, clinically distinct conditions. When the physician explicitly documents both conditions as co-existing, both the diabetic retinopathy combination code AND H35.3111 may be assignable under Excludes 2 logic. This requires clear physician documentation distinguishing the two processes — do not assume dual coding without it, and do not merge AMD drusen into the diabetic retinopathy code.

---

📋 Clinical Overview

Pathophysiology of Early Dry AMD

In early AMD, years of oxidative stress and chronic low-grade inflammation drive extracellular debris accumulation beneath the retinal pigment epithelium (RPE) — the yellow-white deposits visible on fundoscopy as drusen. At the early stage, these are medium-sized (≥63μm to <125μm), arising from lipid-protein complexes, complement pathway byproducts (particularly C3d), and shed RPE organelles accumulating between the RPE basal lamina and Bruch’s membrane.²

The RPE cells themselves remain largely intact at this stage — hence the preserved visual acuity and absence of significant symptoms. However, the accumulating drusen disrupt RPE-photoreceptor metabolic exchange and progressively weaken Bruch’s membrane, setting the stage for the pigmentary changes and RPE dysfunction that define intermediate AMD progression. The complement system plays a central role — variants in CFH, ARMS2, C3, and CFB genes are strongly associated with AMD progression, which is why early AMD identification matters for genetic counseling and family screening.²

Symptoms at the Early Stage

Symptom	Prevalence at Early Stage	Clinical Notes
Asymptomatic	Most common	Early AMD is frequently discovered incidentally
Difficulty with dark adaptation	Occasional	Earlier RPE stress before photoreceptor loss
Mildly reduced contrast sensitivity	Occasional	Not captured by standard Snellen VA testing
Normal reading vision	Expected	20/20-20/30 typical; Snellen VA not sensitive to early AMD
Amsler grid distortion	Rare at early stage	Distortion or central scotoma → suggests progression to intermediate/wet

Normal Snellen VA Does Not Rule Out AMD Progression Risk

Snellen visual acuity (the “20/20” measurement) is relatively insensitive to early and intermediate dry AMD. A patient can have visually significant drusen burden with measurable functional deficits on contrast sensitivity and dark adaptation testing while still reading 20/20 on the Snellen chart. This is why OCT and fundus photography are the primary monitoring tools — not VA alone. Early AMD patients should be counseled to monitor at home with an Amsler grid and report any new distortion or central blur immediately, as these are the first warning signs of conversion to wet AMD.

Risk Factors and Modifiable Prevention²

Risk Factor	Modifiable?	Clinical Action
Age >60	❌	Increased monitoring frequency with age
Smoking (current or history)	✅	Smoking cessation counseling at every visit; 2-4× increased risk
Family history of AMD	❌	Genetic counseling; earlier and more frequent screening of siblings
Cardiovascular disease	✅	Shared vascular risk factor management
Diet low in lutein/zeaxanthin	✅	Leafy greens (spinach, kale) — dietary counseling
UV light exposure	✅	UV-blocking sunglasses counseling
Obesity/BMI >30	✅	Weight management — associated with accelerated progression
Hypertension	✅	Blood pressure control
Light iris color	❌	Document as risk factor

AREDS2 Supplementation — Early Stage Guidance

AREDS2 Is NOT Indicated for Early Dry AMD

This is one of the most important clinical coding and CDI nuances for H35.3111. The AREDS2 formulation (vitamin C 500mg, vitamin E 400IU, lutein 10mg, zeaxanthin 2mg, zinc 80mg, copper 2mg) is indicated to slow progression to advanced AMD in patients with intermediate AMD (H35.3112) or advanced AMD in one eye. It is not indicated at the early stage (H35.3111) because the evidence for benefit at early stage has not been demonstrated, and the supplement carries its own small risk profile (e.g., zinc-related urogenital effects in men).

When a patient is coded as H35.3111 (early dry) but is currently taking AREDS2, query whether the stage documentation is accurate — the ophthalmologist may have intermediary findings that support a higher stage (H35.3112) warranting AREDS2. Conversely, if AREDS2 was started before the most recent classification and the patient truly has early AMD, document that the supplement is being continued from prior intermediate-stage disease.

---

💰 HCC Risk Adjustment (CMS-HCC v28)

Field	Detail
CMS-HCC Model Version	v28 (2024-2025 Implementation)
HCC Assignment	❌ Not Mapped
HCC Category	N/A
RAF Coefficient	0.000
RxHCC Assignment	Not Mapped

H35.3111 carries no HCC weight under CMS-HCC v28.³

RAF Opportunity at the Early AMD Encounter — Comorbidity Capture

While H35.3111 itself contributes no RAF, early AMD patients are overwhelmingly Medicare-aged and frequently carry multiple HCC-bearing comorbidities. At every H35.3111 encounter, review for and ensure complete coding of:

Common AMD Comorbidity	HCC (v28)	RAF Significance
Type 2 diabetes mellitus	HCC 18	High
Coronary artery disease	HCC 85	High
Heart failure	HCC 85	High
Atrial fibrillation	HCC 96	Moderate
CKD Stage 3-5	HCC 137	Moderate
COPD	HCC 111	Moderate
Morbid obesity	HCC 48	Moderate

These conditions meet UHDDS criteria when documented and clinically managed — the ophthalmology encounter may be the only time that year a patient sees a physician who documents them. Every additional diagnosis that qualifies builds the patient’s true risk profile and supports the MA plan’s expected cost modeling.

---

🏥 MS-DRG Assignment

MDC 02 — Diseases and Disorders of the Eye (if principal — extremely rare for early AMD)

DRG	Title	Est. Relative Weight*
DRG 124	Other Disorders of the Eye with MCC	~0.95-1.15
DRG 125	Other Disorders of the Eye with CC	~0.70-0.90
DRG 126	Other Disorders of the Eye without CC/MCC	~0.50-0.70

*Approximate. Verify against IPPS FY2025 Final Rule tables.⁴

Inpatient Context for H35.3111

Early dry AMD will virtually never be the reason for inpatient admission. In the inpatient setting, H35.3111 appears as an additional diagnosis — a documented, clinically active chronic condition relevant to the care episode. Its primary inpatient coding value is supporting completeness of the clinical picture. It does not independently carry CC status and will not drive DRG tier changes on its own.

---

🔗 Related ICD-10-CM Codes

Nonexudative AMD Staging — Early Stage in Context

Code	Description	Drusen	Pigment?	Stage
H35.3110	Right eye, stage unspecified	Unknown	Unknown	⚠️ Query first
H35.3111	Right eye, early dry ← This Code	≥63-<125μm	❌ None	Early
H35.3112	Right eye, intermediate dry	≥125μm or medium + pigment	✅ May be present	Intermediate
H35.3113	Right eye, advanced, no subfoveal GA	Geographic atrophy	✅ Present	Late (non-central)
H35.3114	Right eye, advanced, subfoveal GA	Central GA	✅ Present	Late (central)

Bilateral Equivalent — Same Stage, Both Eyes

Code	Description	Use When
H35.3131	Nonexudative AMD, bilateral, early dry stage	Both eyes document early dry AMD at same stage — use bilateral code
H35.3111 + H35.3121	Right early + left early	Only if stages differ or bilateral code is not documented

Conversion Watch Codes

Code	Description	Trigger for Reassignment
H35.3112	Right eye, intermediate dry	New large drusen (≥125μm) or RPE pigmentary changes documented
H35.3211	Right eye, exudative AMD, active CNV	New subretinal fluid, CNV on FA/OCT-A, hemorrhage, or vision drop

Watch for Wet AMD Conversion — Stop Using H35.3111 Immediately

Approximately 1-3% of early dry AMD eyes convert to wet (exudative) AMD per year. Conversion is heralded by:

• Sudden onset of metamorphopsia (Amsler grid distortion)
• Rapid visual acuity drop
• New subretinal fluid or hemorrhage on OCT
• New CNV on fluorescein angiography or OCT-A

When conversion is documented, H35.3111 must be retired for that eye and replaced with H35.3211 (exudative AMD, right eye, with active CNV) — a completely different disease process requiring urgent anti-VEGF treatment. Continuing to code early dry AMD after documented wet AMD conversion is a significant coding accuracy failure that misrepresents the clinical urgency and treatment intensity.

Associated Codes — Commonly Coded Alongside

Code	Description	Relationship
Z82.1	Family history of blindness and visual loss	Risk factor documentation — supports monitoring medical necessity
F17.210	Nicotine dependence, cigarettes, uncomplicated	Smoking — document when present; modifiable risk factor
Z87.891	Personal history of nicotine dependence	Former smoker — relevant risk factor
H35.3121	Nonexudative AMD, left eye, early dry stage	If left eye is also early stage — consider bilateral code H35.3131 instead
H53.131	Sudden visual loss, right eye	Code if acute VA change prompts the visit — may signal conversion

---

🛠️ Commonly Associated CPT Codes (Ophthalmology)

Standard Monitoring Protocol for H35.3111 — Annual Visits

Early Dry AMD Monitoring Is Annual, Not Quarterly

Unlike intermediate or advanced dry AMD (which may warrant every 3-6 months), early dry AMD is typically monitored annually in the absence of symptoms. This affects the medical necessity documentation required to support high-frequency OCT and fundus photography billing. If claims for 92134 and 92250 are submitted more frequently than annually for H35.3111, payers may request documentation of accelerated monitoring rationale — document any risk factors (family history, high-risk genetic variants, fellow eye status) that justify more frequent surveillance.

CPT Code	Description	H35.3111 Application	Typical Frequency
92004	Ophthalmological exam, comprehensive, new patient	Initial evaluation and AMD diagnosis	Once (new patient)
92014	Ophthalmological exam, comprehensive, established	Annual AMD monitoring visit	Annually
92250	Fundus photography with interpretation	Drusen size, density, and distribution documentation; baseline and annual comparison	Annually
92134	OCT posterior segment	Drusen volume quantification, RPE integrity baseline; supported by CMS LCD for H35.3111	Annually (more often if at higher risk)
92083	Visual field examination	Not routinely indicated at early stage — reserve for symptomatic patients or if neurologic involvement suspected	As needed
92235	Fluorescein angiography	Not routine at early stage — reserve for suspected CNV conversion or when hemorrhage, fluid, or rapid VA drop occurs	As needed / if conversion suspected

OCT-A (Optical Coherence Tomography Angiography) at the Early Stage

OCT angiography (OCT-A) is increasingly used in early dry AMD to detect subclinical CNV — nascent neovascular membranes not yet causing symptoms or visible on conventional OCT. While not yet universally covered by payers for routine early AMD screening, OCT-A can influence staging and prompt earlier conversion to wet AMD coding. When performed and documented, check the applicable payer LCD for coverage under H35.3111.

NCCI Bundling Considerations — Key Pairs

92134 (OCT) Billed Separately from 92250 (Fundus Photography) — Same DOS

Billing 92134 (OCT) and 92250 (fundus photography) on the same date of service requires medical necessity documentation for each, as some payers may apply a NCCI edit or frequency limitation. Both are clinically complementary for AMD monitoring — OCT provides cross-sectional retinal layer analysis while fundus photography provides en-face documentation of drusen topography. Document why both are medically necessary if billed same DOS. Current NCCI PTP edit status should be verified for the applicable fiscal year.

---

🔬 ICD-10-PCS Crosswalk (Inpatient)

No Routine Inpatient Procedures for Early Dry AMD

There are no standard ICD-10-PCS procedures associated with early dry AMD in the inpatient setting. Early AMD is managed by monitoring, lifestyle counseling, and smoking cessation. No laser, injection, or surgical intervention is indicated at this stage. If a patient with H35.3111 is admitted for a systemic condition and undergoes a fundus examination documented in the record, that exam does not generate a billable ICD-10-PCS procedure code in the inpatient setting — diagnostic examinations are bundled.

---

💊 Coding Scenarios and Examples

---

Scenario 1 — Early Dry AMD Discovered at Annual Eye Exam, Right Eye Only (Outpatient)

Clinical Vignette: A 68-year-old female presents for her annual dilated eye examination. She is asymptomatic. Fundoscopic examination reveals several medium-sized drusen (approximately 75-100μm) at the posterior pole of the right eye, without pigmentary abnormalities. Left eye is normal. OCT confirms drusen deposits without RPE atrophy or subretinal fluid, right eye. Visual acuity 20/20 OU. Amsler grid normal OU. Impression: Early dry AMD, right eye. Patient counseled on Amsler grid home monitoring, smoking cessation (current smoker), UV protection, and Mediterranean diet. Annual follow-up scheduled.

CPT Codes:

• 92004 — Comprehensive ophthalmological exam, new patient (first presentation)
• 92134 — OCT posterior segment (drusen characterization and baseline documentation)
• 92250 — Fundus photography with interpretation and report (baseline documentation)

ICD-10-CM:

• H35.3111 — Nonexudative AMD, right eye, early dry stage (medium drusen, no pigment changes, right eye — this is the correct billable 7-character code)
• F17.210 — Nicotine dependence, cigarettes, uncomplicated (active smoker — significant modifiable risk factor; document and code)

Left Eye — Is There an AMD Code?

In this scenario the left eye is documented as normal (no drusen, no pigment changes). Do NOT assign any AMD code for the left eye — coding requires documentation of actual findings. If the left eye had small drusen only (drupelets, <63μm), those represent normal aging and are also not coded as AMD. Only when the left eye has documented ≥63μm drusen does an H35.312x code apply.

---

Scenario 2 — Early Dry AMD, Right Eye — Asymmetric Bilateral AMD (Outpatient)

Clinical Vignette: A 74-year-old retired teacher presents for 6-month follow-up of known AMD. Right eye: medium drusen (70-90μm), no pigmentary changes — unchanged from last visit. Left eye: large drusen (>125μm) noted at last visit, now with new focal RPE hyperpigmentation. Visual acuity: 20/25 OD, 20/40 OS. OCT confirms stable right eye drusen; left eye shows progressive change. Impression: Early dry AMD, right eye (stable). Intermediate dry AMD, left eye (progressed — AREDS2 supplementation recommended).

CPT Codes:

• 92014 — Comprehensive ophthalmological exam, established patient
• 92134 — OCT posterior segment (bilateral comparison — both eyes)
• 92250 — Fundus photography (bilateral — progression documentation)

ICD-10-CM:

• H35.3111 — Nonexudative AMD, right eye, early dry stage (right eye unchanged — still early)
• H35.3122 — Nonexudative AMD, left eye, intermediate dry stage (left eye progressed — NEW pigment changes + large drusen = intermediate; AREDS2 now indicated)

Asymmetric Staging — Do Not Use Bilateral Code

When the two eyes are at different stages, assign separate laterality-specific codes for each eye. A bilateral code (H35.313x) would require both eyes to be at the same stage. Here, right eye is early (H35.3111) and left eye has progressed to intermediate (H35.3122) — these must be coded separately. The stage progression in the left eye also represents a CDI and documentation opportunity: the physician’s record should explicitly document the reclassification from early to intermediate based on the new pigment changes, as this drives both code assignment and AREDS2 medical necessity.

---

Scenario 3 — Early Dry AMD Inpatient — Additional Diagnosis (Inpatient Hip Replacement)

Clinical Vignette: An 82-year-old male is admitted for elective right total hip arthroplasty. H&P documents medical history including: hypertension, type 2 diabetes (diet-controlled), and early dry AMD, right eye — noted as currently followed by ophthalmology annually, no recent changes. Vision intact. No intraoperative considerations for AMD noted.

Principal Diagnosis:

• Z96.641 — Presence of right artificial hip joint (or the primary arthroplasty code — per facility convention)

Additional Diagnoses:

• H35.3111 — Nonexudative AMD, right eye, early dry stage (documented in H&P as active chronic condition)
• E11.9 — Type 2 DM without complications (documented, diet-controlled)
• I10 — Essential hypertension (documented)

MS-DRG Assignment:

• Groups to MDC 08 (Musculoskeletal) — NOT MDC 02; hip arthroplasty is principal

Why Code H35.3111 in the Inpatient Setting for a Hip Case?

UHDDS guidelines require coding all conditions that “coexist at the time of admission, that develop subsequently, or that affect the treatment received and/or the length of stay.” Early dry AMD meets this criterion when it is documented as an active condition in the H&P, even if it does not directly influence surgical care. In an elderly patient, the documented AMD status is clinically relevant to:

• Fall risk assessment (vision status affects physical therapy planning)
• Discharge disposition (vision impairment affects ability to manage at home)
• Accurate comorbidity profile documentation for quality metrics and readmission risk scoring

Code it when it’s documented and clinically active — omitting it understates the patient’s overall burden of chronic disease.

---

Scenario 4 — Documentation Says “AMD” Without Stage — Query Required

Clinical Vignette: A coder reviews an outpatient ophthalmology note. The impression reads: “AMD, right eye — medium drusen noted, no pigmentary changes, no fluid, annual follow-up.” The physician did not use the words “early,” “intermediate,” or “advanced.” The coder is deciding between H35.3111 and H35.3110.

Appropriate Action:

1. The documentation describes medium drusen and no pigmentary changes — this is the clinical definition of early dry AMD per the Beckman classification [web:78]
2. The coder CAN assign H35.3111 because the clinical criteria are explicitly documented in the note, even without the word “early” — the drusen size and absence of pigment changes establish the stage
3. If drusen size is not documented, assign H35.3110 (stage unspecified) and submit a CDI query asking the physician to specify the AMD stage
4. If the physician responds with “early” → correct to H35.3111; if “intermediate” → H35.3112

Clinical Findings Can Establish Stage Without the Word "Early"

Unlike some diagnoses that require explicit physician terminology, AMD staging is directly tied to documented objective findings (drusen size, pigmentary changes, geographic atrophy presence). When those findings are explicitly documented — even without stage labeling — the coder may assign the clinically accurate stage code. This mirrors the ICD-10-CM guidance on coding from clinical indicators. However, if findings are absent or ambiguous, H35.3110 (stage unspecified) + CDI query is the appropriate interim approach.

---

⚠️ Coding Pitfalls and Tips

	Pitfall or Tip
❌	Never submit H35.311 (6-character) as a billable code — it will reject; H35.3111 (7 characters) is required
❌	Do not assign H35.3111 when drusen are <63μm only — small drusen (drupelets) represent normal aging, not AMD; no code is appropriate
❌	Do not assign H35.3111 when pigmentary changes are present — even a single area of AMD-associated RPE hyperpigmentation or hypopigmentation upgrades the stage to H35.3112 (intermediate)
❌	Do not assign H35.3111 if diabetes is the documented etiology of macular changes — use diabetic retinopathy combination code per Excludes 2
❌	Do not continue using H35.3111 after wet AMD conversion — once CNV is documented, retire H35.3111 and assign H35.3211 (exudative AMD, right eye, active CNV)
❌	Do not assume AREDS2 supplementation means intermediate AMD — but do query when a patient with H35.3111 is on AREDS2; they may actually have intermediate disease that wasn’t staged in prior documentation
✅	Code smoking status alongside H35.3111 — smoking is the most significant modifiable risk factor for AMD progression; F17.210 or Z87.891 adds clinical context and supports counseling documentation
✅	Use bilateral code H35.3131 when both eyes have confirmed early dry AMD at the same stage — don’t code right and left separately when bilateral is accurate
✅	Use separate laterality codes when AMD stages differ between the two eyes — document each eye’s stage explicitly in the record
✅	Clinical findings can establish stage — medium drusen + no pigment changes documented in the note supports H35.3111 even without the word “early”; but if findings are absent or unclear, query before assigning the stage
✅	Counsel patients to use the Amsler grid and document this in the record — any new distortion is the earliest symptom of CNV conversion and drives a code change to H35.3211
✅	At the annual AMD visit, sweep for HCC comorbidities — DM, CAD, CKD, atrial fibrillation — these co-occurring conditions carry RAF weight and meet UHDDS criteria for coding

---

📚 Sources

1. CMS/NCHS. ICD-10-CM Official Guidelines for Coding and Reporting, FY2025; Tabular List — H35.31 Nonexudative AMD, 7th character staging instructions; H35 Excludes 2 notation; General Coding Guidelines Section I.B — Laterality; Section I.B.4 — Signs, Symptoms, and Codes for Clinical Findings.

2. Freund KB, Sarraf D, Mieler WF, Yannuzzi LA. The Retinal Atlas, 2nd ed. Elsevier; 2017. Chapter on Age-Related Macular Degeneration — nonexudative staging, pathophysiology, and clinical management.

3. Ferris FL, Wilkinson CP, Bird A, et al. “Clinical Classification of Age-related Macular Degeneration.” Ophthalmology. 2013;120(4):844-851. (Beckman Initiative for Macular Research Classification Committee — medium drusen early AMD definition.) [web:86]

4. CMS. IPPS Final Rule FY2025 — MS-DRG Definitions Manual v42. MDC 02 — Diseases and Disorders of the Eye, DRGs 124-126.

5. Age-Related Eye Disease Study Research Group. “A Randomized, Placebo-Controlled Clinical Trial of High-Dose Supplementation with Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss.” Arch Ophthalmol. 2001;119(10):1417-1436. AREDS2 Research Group, JAMA. 2013;309(19):2005-2015. AREDS2 indication limited to intermediate AMD and beyond.

6. Eyes on Eyecare. “How To Accurately Stage Age-Related Macular Degeneration.” February 2026. Beckman classification criteria — drusen size thresholds and pigmentary change requirements for staging. [web:78]

7. CMS. Local Coverage Article: Billing and Coding: Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI). Article A56916; revised 2024. H35.3111 confirmed as covered diagnosis for 92134.

8. CMS. 2024 Medicare Advantage Risk Adjustment — CMS-HCC Model v28 ICD-10-CM Mappings. Baltimore, MD: Centers for Medicare & Medicaid Services.

9. icdlist.com. “ICD-10-CM Diagnosis Code H35.3111 — Nonexudative age-related macular degeneration, right eye, early dry stage.” Confirmed billable 7-character code, FY2025. [web:76]